. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: Gastroenterology. 2017 Feb 14;152(8):1915–1921.e1. doi: 10.1053/j.gastro.2017.02.005

Table 4.

Time since discontinuation of menopausal hormone therapy among women who stopped taking hormones and risk of incident fecal incontinence

	Years since discontinuation
	Never	≥2	<2	Current
Person-years of follow up	41,870	4,780	110,746	20,805

No. of cases	1304	251	4,097	720

Age-adjusted HR (95% CI)	1.00	1.14 (1.00–1.30)	1.29 (1.21–1.37)	1.34 (1.22–1.47)

Multivariate-adjusted HR (95% CI)^a.	1.00	1.08 (0.95–1.23)	1.25 (1.17–1.34)	1.34 (1.22–1.47)

Models adjusted for age (months), age at menopause (years), smoking (never, past, current), BMI (<20, 20–24.9, 25–29.9, >30 kg/m²), oral contraceptive use (never, ever), parity (0, 1, 2, ≥3), age at menarche (?≤10, 11, 12, 13, ≥14), menopause type (natural, surgical/radiation), ovulatory duration (<24 years, 24–29 years, 29–33 years, ≥34 years), hypertension (yes/no), diabetes mellitus (yes/no), neurologic disease (yes/no), years working night shifts, and history of cholecystectomy (yes/no).

There were 4,828 women with missing data on time since discontinuation of MHT representing 462 cases of fecal incontinence who were not included in this analysis.